US 8809264
Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors
granted A61KA61K38/212A61K38/215
Quick answer
US patent 8809264 (Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K38/212, A61K38/215, A61P, A61P1/16